Gut microbiota-derived metabolite phenylacetylglutamine in cardiovascular and metabolic diseases

The aging of population coupled with unhealthy dietary habits among residents has led to a rise in the incidence of cardiovascular and metabolic diseases (CVMDs). Extensive research has highlighted the role of gut microbiota-derived metabolites in CVMDs. Among these metabolites, phenylacetylglutamin...

Full description

Saved in:
Bibliographic Details
Main Authors: Wan Chen, Mei-Ling Li, Guang Zeng, Xiang-Yu Xu, Shan-Hui Yin, Can Xu, Linlin Li, Kaikai Wen, Xiao-Hua Yu, Gang Wang
Format: Article
Language:English
Published: Elsevier 2025-07-01
Series:Pharmacological Research
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1043661825002191
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849719689423355904
author Wan Chen
Mei-Ling Li
Guang Zeng
Xiang-Yu Xu
Shan-Hui Yin
Can Xu
Linlin Li
Kaikai Wen
Xiao-Hua Yu
Gang Wang
author_facet Wan Chen
Mei-Ling Li
Guang Zeng
Xiang-Yu Xu
Shan-Hui Yin
Can Xu
Linlin Li
Kaikai Wen
Xiao-Hua Yu
Gang Wang
author_sort Wan Chen
collection DOAJ
description The aging of population coupled with unhealthy dietary habits among residents has led to a rise in the incidence of cardiovascular and metabolic diseases (CVMDs). Extensive research has highlighted the role of gut microbiota-derived metabolites in CVMDs. Among these metabolites, phenylacetylglutamine (PAGln), a meta-organismal prothrombotic metabolite, has been proved to promote the progression of CVMDs. This bacterial derived metabolite is a byproduct of amino acid comes from phenylalanine (Phe) in the diet. There are increasing evidence showing that the level of PAGln is associated with the risk of developing CVMDs. To provide a comprehensive understanding of the role of PAGln in CVMDs, this review delves into the production and metabolic pathways of PAGln and discusses the links of PAGln and the pathogenesis of CVMDs.
format Article
id doaj-art-b58e650beec241c1a58a3ad0c86affcc
institution DOAJ
issn 1096-1186
language English
publishDate 2025-07-01
publisher Elsevier
record_format Article
series Pharmacological Research
spelling doaj-art-b58e650beec241c1a58a3ad0c86affcc2025-08-20T03:12:05ZengElsevierPharmacological Research1096-11862025-07-0121710779410.1016/j.phrs.2025.107794Gut microbiota-derived metabolite phenylacetylglutamine in cardiovascular and metabolic diseasesWan Chen0Mei-Ling Li1Guang Zeng2Xiang-Yu Xu3Shan-Hui Yin4Can Xu5Linlin Li6Kaikai Wen7Xiao-Hua Yu8Gang Wang9The First Affiliated Hospital, Department of Cardiology, Hengyang Medical school, University of South China, Hengyang, Hunan 421001, China; Beijing Institute of Nanoenergy and Nanosystems, Chinese Academy of Sciences, Beijing 101400, ChinaThe First Affiliated Hospital, Department of Cardiology, Hengyang Medical school, University of South China, Hengyang, Hunan 421001, ChinaThe First Affiliated Hospital, Department of Cardiology, Hengyang Medical school, University of South China, Hengyang, Hunan 421001, ChinaThe First Affiliated Hospital, Department of Cardiology, Hengyang Medical school, University of South China, Hengyang, Hunan 421001, ChinaThe First Affiliated Hospital, Department of Cardiology, Hengyang Medical school, University of South China, Hengyang, Hunan 421001, ChinaThe First Affiliated Hospital, Department of Cardiology, Hengyang Medical school, University of South China, Hengyang, Hunan 421001, ChinaBeijing Institute of Nanoenergy and Nanosystems, Chinese Academy of Sciences, Beijing 101400, ChinaBeijing Institute of Nanoenergy and Nanosystems, Chinese Academy of Sciences, Beijing 101400, China; Corresponding authors.Institute of Clinical Medicine, The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan 570100, China; Corresponding authors.The First Affiliated Hospital, Department of Cardiology, Hengyang Medical school, University of South China, Hengyang, Hunan 421001, China; Corresponding authors.The aging of population coupled with unhealthy dietary habits among residents has led to a rise in the incidence of cardiovascular and metabolic diseases (CVMDs). Extensive research has highlighted the role of gut microbiota-derived metabolites in CVMDs. Among these metabolites, phenylacetylglutamine (PAGln), a meta-organismal prothrombotic metabolite, has been proved to promote the progression of CVMDs. This bacterial derived metabolite is a byproduct of amino acid comes from phenylalanine (Phe) in the diet. There are increasing evidence showing that the level of PAGln is associated with the risk of developing CVMDs. To provide a comprehensive understanding of the role of PAGln in CVMDs, this review delves into the production and metabolic pathways of PAGln and discusses the links of PAGln and the pathogenesis of CVMDs.http://www.sciencedirect.com/science/article/pii/S1043661825002191Cardiovascular diseasesMetabolic diseasesGut microbiotaGut microbiota-derived metabolitePhenylacetylglutamine
spellingShingle Wan Chen
Mei-Ling Li
Guang Zeng
Xiang-Yu Xu
Shan-Hui Yin
Can Xu
Linlin Li
Kaikai Wen
Xiao-Hua Yu
Gang Wang
Gut microbiota-derived metabolite phenylacetylglutamine in cardiovascular and metabolic diseases
Pharmacological Research
Cardiovascular diseases
Metabolic diseases
Gut microbiota
Gut microbiota-derived metabolite
Phenylacetylglutamine
title Gut microbiota-derived metabolite phenylacetylglutamine in cardiovascular and metabolic diseases
title_full Gut microbiota-derived metabolite phenylacetylglutamine in cardiovascular and metabolic diseases
title_fullStr Gut microbiota-derived metabolite phenylacetylglutamine in cardiovascular and metabolic diseases
title_full_unstemmed Gut microbiota-derived metabolite phenylacetylglutamine in cardiovascular and metabolic diseases
title_short Gut microbiota-derived metabolite phenylacetylglutamine in cardiovascular and metabolic diseases
title_sort gut microbiota derived metabolite phenylacetylglutamine in cardiovascular and metabolic diseases
topic Cardiovascular diseases
Metabolic diseases
Gut microbiota
Gut microbiota-derived metabolite
Phenylacetylglutamine
url http://www.sciencedirect.com/science/article/pii/S1043661825002191
work_keys_str_mv AT wanchen gutmicrobiotaderivedmetabolitephenylacetylglutamineincardiovascularandmetabolicdiseases
AT meilingli gutmicrobiotaderivedmetabolitephenylacetylglutamineincardiovascularandmetabolicdiseases
AT guangzeng gutmicrobiotaderivedmetabolitephenylacetylglutamineincardiovascularandmetabolicdiseases
AT xiangyuxu gutmicrobiotaderivedmetabolitephenylacetylglutamineincardiovascularandmetabolicdiseases
AT shanhuiyin gutmicrobiotaderivedmetabolitephenylacetylglutamineincardiovascularandmetabolicdiseases
AT canxu gutmicrobiotaderivedmetabolitephenylacetylglutamineincardiovascularandmetabolicdiseases
AT linlinli gutmicrobiotaderivedmetabolitephenylacetylglutamineincardiovascularandmetabolicdiseases
AT kaikaiwen gutmicrobiotaderivedmetabolitephenylacetylglutamineincardiovascularandmetabolicdiseases
AT xiaohuayu gutmicrobiotaderivedmetabolitephenylacetylglutamineincardiovascularandmetabolicdiseases
AT gangwang gutmicrobiotaderivedmetabolitephenylacetylglutamineincardiovascularandmetabolicdiseases